{"schema_version":"secwatch.filing_event.v1","accession":"0001079973-26-001110","form_type":"8-K","ticker":"LCTC","cik":"0001493137","company_name":"Lifeloc Technologies, Inc","filed_at":"2026-08-14T19:43:42+00:00","discovered_at":"2026-08-14T19:45:03.783593+00:00","generated_at":"2026-08-14T19:45:11.361327+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Lifeloc Q2 2026 revenue up 10% to $2.445M, net loss narrows to $(134K)","bullets":["Q2 2026 net revenue $2.445M, up 10% YoY; net loss $(134K) or $(0.05) diluted vs $(394K) or $(0.14) in Q2 2025.","Six-month revenue $4.739M, loss $(287K) or $(0.10) vs $4.496M and $(686K) or $(0.25) prior year.","Gross margin improved to 45% from 42% YoY; R&D spend $560K on SpinDetect analyzer development.","SpinDetect oral-fluid analyzer beta testing to start; limited commercial launch targeted for Q1 2027.","Closed $500K loan from Chairman/CFO at 10.5% interest, secured by all assets, to fund operations."],"urls":{"canonical":"https://secwatch.observer/filing/0001079973-26-001110","json":"https://secwatch.observer/filing/0001079973-26-001110.json","markdown":"https://secwatch.observer/filing/0001079973-26-001110.md","text":"https://secwatch.observer/filing/0001079973-26-001110.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1493137/000107997326001110/0001079973-26-001110-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1493137/000107997326001110/lctc_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-14T19:45:11.361327+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}